vs
Side-by-side financial comparison of Essex Property Trust (ESS) and HAEMONETICS CORP (HAE). Click either name above to swap in a different company.
Essex Property Trust is the larger business by last-quarter revenue ($479.6M vs $339.0M, roughly 1.4× HAEMONETICS CORP). Essex Property Trust runs the higher net margin — 17.9% vs 13.2%, a 4.7% gap on every dollar of revenue. On growth, Essex Property Trust posted the faster year-over-year revenue change (5.5% vs -2.7%). Over the past eight quarters, Essex Property Trust's revenue compounded faster (6.0% CAGR vs 0.4%).
Essex Property Trust is a publicly traded real estate investment trust that invests in apartments in California and in the Seattle metropolitan area.
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
ESS vs HAE — Head-to-Head
Income Statement — Q4 FY2025 vs Q3 FY2026
| Metric | | |
|---|---|---|
| Revenue | $479.6M | $339.0M |
| Net Profit | $85.7M | $44.7M |
| Gross Margin | 70.0% | 59.7% |
| Operating Margin | 31.7% | 19.9% |
| Net Margin | 17.9% | 13.2% |
| Revenue YoY | 5.5% | -2.7% |
| Net Profit YoY | -71.6% | 19.3% |
| EPS (diluted) | $1.24 | $0.95 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $479.6M | $339.0M | ||
| Q3 25 | $473.3M | $327.3M | ||
| Q2 25 | $469.8M | $321.4M | ||
| Q1 25 | $464.6M | $330.6M | ||
| Q4 24 | $454.5M | $348.5M | ||
| Q3 24 | $450.7M | $345.5M | ||
| Q2 24 | $442.4M | $336.2M | ||
| Q1 24 | $426.9M | — |
| Q4 25 | $85.7M | $44.7M | ||
| Q3 25 | $172.7M | $38.7M | ||
| Q2 25 | $231.5M | $34.0M | ||
| Q1 25 | $212.8M | $58.0M | ||
| Q4 24 | $301.7M | $37.5M | ||
| Q3 24 | $125.5M | $33.8M | ||
| Q2 24 | $99.0M | $38.4M | ||
| Q1 24 | $285.1M | — |
| Q4 25 | 70.0% | 59.7% | ||
| Q3 25 | 69.2% | 59.5% | ||
| Q2 25 | 70.7% | 59.8% | ||
| Q1 25 | 69.6% | 58.4% | ||
| Q4 24 | 70.0% | 55.5% | ||
| Q3 24 | 69.5% | 54.2% | ||
| Q2 24 | 70.8% | 52.0% | ||
| Q1 24 | 69.7% | — |
| Q4 25 | 31.7% | 19.9% | ||
| Q3 25 | 44.5% | 17.9% | ||
| Q2 25 | 59.5% | 16.8% | ||
| Q1 25 | 55.3% | 21.6% | ||
| Q4 24 | 67.0% | 16.9% | ||
| Q3 24 | 28.6% | 15.0% | ||
| Q2 24 | 31.1% | 11.8% | ||
| Q1 24 | 31.0% | — |
| Q4 25 | 17.9% | 13.2% | ||
| Q3 25 | 36.5% | 11.8% | ||
| Q2 25 | 49.3% | 10.6% | ||
| Q1 25 | 45.8% | 17.5% | ||
| Q4 24 | 66.4% | 10.8% | ||
| Q3 24 | 27.8% | 9.8% | ||
| Q2 24 | 22.4% | 11.4% | ||
| Q1 24 | 66.8% | — |
| Q4 25 | $1.24 | $0.95 | ||
| Q3 25 | $2.56 | $0.81 | ||
| Q2 25 | $3.44 | $0.70 | ||
| Q1 25 | $3.16 | $1.17 | ||
| Q4 24 | $4.00 | $0.74 | ||
| Q3 24 | $1.84 | $0.66 | ||
| Q2 24 | $1.45 | $0.74 | ||
| Q1 24 | $4.25 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $76.2M | $363.4M |
| Total DebtLower is stronger | — | $1.2B |
| Stockholders' EquityBook value | $5.5B | $911.5M |
| Total Assets | $13.2B | $2.5B |
| Debt / EquityLower = less leverage | — | 1.34× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $76.2M | $363.4M | ||
| Q3 25 | $66.0M | $296.4M | ||
| Q2 25 | $58.7M | $292.9M | ||
| Q1 25 | $98.7M | $306.8M | ||
| Q4 24 | $66.8M | $320.8M | ||
| Q3 24 | $71.3M | $299.3M | ||
| Q2 24 | $55.2M | $344.4M | ||
| Q1 24 | $499.0M | — |
| Q4 25 | — | $1.2B | ||
| Q3 25 | $6.4B | $1.2B | ||
| Q2 25 | $6.4B | $1.2B | ||
| Q1 25 | $6.8B | $1.2B | ||
| Q4 24 | — | — | ||
| Q3 24 | $6.4B | — | ||
| Q2 24 | $6.2B | — | ||
| Q1 24 | $6.6B | — |
| Q4 25 | $5.5B | $911.5M | ||
| Q3 25 | $5.6B | $849.2M | ||
| Q2 25 | $5.6B | $882.3M | ||
| Q1 25 | $5.6B | $820.8M | ||
| Q4 24 | $5.5B | $906.9M | ||
| Q3 24 | $5.4B | $878.9M | ||
| Q2 24 | $5.5B | $905.4M | ||
| Q1 24 | $5.5B | — |
| Q4 25 | $13.2B | $2.5B | ||
| Q3 25 | $13.2B | $2.4B | ||
| Q2 25 | $13.2B | $2.5B | ||
| Q1 25 | $13.2B | $2.5B | ||
| Q4 24 | $12.9B | $2.5B | ||
| Q3 24 | $12.6B | $2.5B | ||
| Q2 24 | $12.5B | $2.5B | ||
| Q1 24 | $12.9B | — |
| Q4 25 | — | 1.34× | ||
| Q3 25 | 1.15× | 1.44× | ||
| Q2 25 | 1.14× | 1.39× | ||
| Q1 25 | 1.22× | 1.49× | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.18× | — | ||
| Q2 24 | 1.13× | — | ||
| Q1 24 | 1.19× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.1B | $93.6M |
| Free Cash FlowOCF − Capex | — | $87.2M |
| FCF MarginFCF / Revenue | — | 25.7% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | 12.53× | 2.09× |
| TTM Free Cash FlowTrailing 4 quarters | — | $308.1M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.1B | $93.6M | ||
| Q3 25 | $342.6M | $111.3M | ||
| Q2 25 | $216.1M | $17.4M | ||
| Q1 25 | $281.5M | $116.6M | ||
| Q4 24 | $1.1B | $43.8M | ||
| Q3 24 | $316.2M | $48.8M | ||
| Q2 24 | $218.9M | $-27.4M | ||
| Q1 24 | $314.9M | — |
| Q4 25 | — | $87.2M | ||
| Q3 25 | — | $106.3M | ||
| Q2 25 | — | $13.6M | ||
| Q1 25 | — | $100.9M | ||
| Q4 24 | — | $35.2M | ||
| Q3 24 | — | $39.4M | ||
| Q2 24 | — | $-33.1M | ||
| Q1 24 | — | — |
| Q4 25 | — | 25.7% | ||
| Q3 25 | — | 32.5% | ||
| Q2 25 | — | 4.2% | ||
| Q1 25 | — | 30.5% | ||
| Q4 24 | — | 10.1% | ||
| Q3 24 | — | 11.4% | ||
| Q2 24 | — | -9.8% | ||
| Q1 24 | — | — |
| Q4 25 | — | 1.9% | ||
| Q3 25 | — | 1.5% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 4.7% | ||
| Q4 24 | — | 2.5% | ||
| Q3 24 | — | 2.7% | ||
| Q2 24 | — | 1.7% | ||
| Q1 24 | — | — |
| Q4 25 | 12.53× | 2.09× | ||
| Q3 25 | 1.98× | 2.88× | ||
| Q2 25 | 0.93× | 0.51× | ||
| Q1 25 | 1.32× | 2.01× | ||
| Q4 24 | 3.54× | 1.17× | ||
| Q3 24 | 2.52× | 1.44× | ||
| Q2 24 | 2.21× | -0.71× | ||
| Q1 24 | 1.10× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESS
Segment breakdown not available.
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
